---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-22-002915"
form_type: "8-K"
ticker: "ITGR"
cik: "0001114483"
company_name: "Integer Holdings Corp"
filed_at: "2022-04-28T23:59:59+00:00"
generated_at: "2026-06-26T03:07:52.651996+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Integer Q1 sales up 7% to $311M, adjusted EPS down 20%; guidance raised for Aran Biomedical acquisition

## Summary
- Sales $311M (+7% YoY); GAAP net income $11M (-47%); adjusted net income $26M (-19%).
- GAAP diluted EPS $0.34; non-GAAP adjusted EPS $0.78, down 20% YoY.
- Acquired Aran Biomedical on April 6, 2022; adds ~$90M annualized sales at accretive growth.
- FY2022 outlook: sales $1.36-1.38B (11-13% growth), adj. EBITDA $273-285M (12-17% growth).
- Cardio & Vascular sales +13%; Cardiac Rhythm +1%; Electrochem +18%; Advanced Surgical -2%.

## SEC filing metadata
- accession: 0001171843-22-002915
- form_type: 8-K
- ticker: ITGR
- cik: 0001114483
- company_name: Integer Holdings Corp
- filed_at: 2022-04-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1114483/000117184322002915/0001171843-22-002915-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1114483/000117184322002915/f8k_042822.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-22-002915
- JSON: https://secwatch.observer/filing/0001171843-22-002915.json
- Plain text: https://secwatch.observer/filing/0001171843-22-002915.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.